Prognostic immunologic signatures in epithelial ovarian cancer
- 14 January 2022
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 41 (10) , 1389-1396
Abstract
Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.Keywords
This publication has 47 references indexed in Scilit:
- Conservation of immune gene signatures in solid tumors and prognostic implicationsBMC Cancer, 2016
- Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)Annals of Oncology, 2016
- Bevacizumab in ovarian cancer: A critical review of phase III studiesOncotarget, 2016
- Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous CarcinomaClinical Cancer Research, 2016
- Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progressionScientific Reports, 2015
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian CancerJournal of Clinical Oncology, 2015
- A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancerBritish Journal of Cancer, 2015
- Differing Clinical Impact of BRCA1 and BRCA2 Mutations in Serous Ovarian CancerPharmacogenomics, 2012
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 lossLaboratory Investigation, 2009
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003